Actelion amends its financial reporting schedule
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Actelion amends its financial reporting schedule
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
ALLSCHWIL, SWITZERLAND - 10 April 2017 - Actelion Ltd (SIX: ATLN) announced
today that it has amended its reporting schedule by discontinuing the reporting
of first quarter and third quarter financial results with immediate effect.
Consequentially Actelion will not be reporting the first quarter 2017 financial
results.
###
ABOUT ACTELION LTD.
Actelion Ltd. is a leading biopharmaceutical company focused on the discovery,
development and commercialization of innovative drugs for diseases with
significant unmet medical needs.
Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our
portfolio of PAH treatments covers the spectrum of disease, from WHO Functional
Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.
Although not available in all countries, Actelion has treatments approved by
health authorities for a number of specialist diseases including Type 1 Gaucher
disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from
systemic sclerosis, and mycosis fungoides in patients with cutaneous T-cell
lymphoma.
Founded in late 1997, with now over 2,600 dedicated professionals covering all
key markets around the world including the US, Japan, China, Russia and Mexico,
Actelion has its corporate headquarters in Allschwil / Basel, Switzerland.
Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as
part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks
are legally protected.
For further information please contact:
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
www.actelion.com
Press release PDF:
http://hugin.info/131801/R/2095252/792430.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Alabama Graphite Corp. Announces Research Partnership with United States Department of Energy’s Oak Ridge National Laboratory; Receives Positive Preliminary Battery-Ready Graphite Test ResultsDatum: 10.04.2017 - 17:35 Uhr
Sprache: Deutsch
News-ID 535533
Anzahl Zeichen: 2743
contact information:
Town:
Allschwil
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 226 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion amends its financial reporting schedule"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
